Professor Byrne trained as a clinical scientist in the UK and the US, at Cardiff, Cambridge and Stanford Universities. He undertook a PhD studying liver lipid metabolism at Cambridge University. He was a post-doctoral fellow at Stanford University and then an MRC fellow at Cambridge University. He was appointed to the Chair of Endocrinology & Metabolism at the University of Southampton in 1999 and was inaugural Director of the Welcome Trust Clinical Research Facility at Southampton until 2004. He is currently Principal Investigator within the NIHR Southampton Biomedical Research Centre and is Consultant Metabolic Physician at University Hospitals Southampton. He has published ~300 publications related to metabolic syndrome and NAFLD and he was a former recipient of the Dorothy Hodgkin prize awarded by Diabetes UK for international research excellence related to diabetes.
Prof. Chris Byrne (UK) discusses NAFLD as a multisystem disease and how NAFLD is a risk factor for other extra hepatic diseases beyond the liverRead More
It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.Read More
Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults.
Previous studies demonstrated conflicting results regarding the association between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF). The statistical power was not sufficient because of modest sample sizes of these studies. We analyzed a large population-based cohort to evaluate the association between NAFLD and AF...
Increased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: a cohort study.
NAFLD has been suggested to be a risk factor associated with low BMD (bone mineral density) in several cross-sectional studies. This longitudinal cohort study aims to explore the effect of NAFLD and its severity on low BMD.Read More
Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity.
Non-alcoholic fatty liver disease (NAFLD) is considered a hepatic manifestation of metabolic syndrome and is associated with cardiovascular outcomes. The authors investigated whether NAFLD was associated with coronary artery calcification (CAC) in participants without a previous history of cardiovascular disease and whether this association differed...Read More
The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.
The authors investigated the association between nonalcoholic fatty liver disease (NAFLD) and gastrointestinal tract cancer in the general population. Retrospective data on individuals aged ≥20 years who received healthcare checkups from January 1, 2009 to December 31, 2009 were analyzed using the National Health Insurance Database in Korea. NAFLD was defined...
auses of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol related Fatty Liver Disease (AFLD).
Non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD) both represent a spectrum of liver disease severity from hepatic steatosis to fibrosis and cirrhosis. It is often not possible to distinguish between NAFLD and AFLD on examination of liver histology, consequently, differentiation between NAFLD and AFLD is heavily reliant...
Fibroblast growth factor signalling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
Fibroblast growth factors and their receptors play an important role in maintaining metabolic homeostasis also in the liver and disorders in signalling what have been identified to contribute to those pathophysiologic conditions leading to hepatic lipid accumulation and chronic inflammation. While specific and well tolerated inhibitors...
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health problem, affecting up to a quarter of the world’s adult population. The burden of NAFLD is influenced by the epidemics of obesity and type 2 diabetes mellitus (T2DM) and the prevalence of these conditions is not expected to decrease in the forthcoming decades...
Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease. It is not well understood, however, which individuals with NAFLD are at highest risk for cardiovascular disease. This study aimed to determine the factors associated with incident cardiovascular events in a prospective cohort of individuals...
Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.
Non-alcoholic fatty liver disease (NAFLD) is associated with high cardiovascular morbidity/mortality, including heart failure. Abnormalities in left ventricular (LV) structure/function are associated with heart failure risk. Participants from the population-based CARDIA (Coronary Artery Risk Development in Young Adults) study...